Adjuvant Immunotherapy after Kidney Cancer Surgery Received FDA Approval

On November 17, 2021, the FDA (US Food and Drug Administration) approved, for adjuvant treatment of renal cell carcinoma (kidney cancer) at intermediate-high risk of recurrence after surgery, the immunotherapy drug pembrolizumab (Keytruda, Merck). This marked the first FDA approval of an immunotherapy drug for adjuvant (protective) treatment after kidney cancer surgery.
Surgery and Adjuvant Immunotherapy in Kidney Cancer – What Is the Benefit? Who Is It Suitable For?
Until 2021, the only drug approved for adjuvant treatment in kidney cancer was the targeted drug sunitinib. However, sunitinib's numerous side effects and inadequate survival outcomes prevented it from reaching the expected level of use in clinical practice.
You can find detailed information about surgery and postoperative treatment in kidney cancer in our video below:
Adjuvant Treatment in Kidney Cancer
Until now, the only FDA-approved drug for postoperative adjuvant treatment in kidney cancer has been sunitinib, which received this approval in 2017 (see the related approval). However, sunutinib did not achieve the desired use in clinical practice, probably because of its numerous side effects, lack of improvement in quality of life and unsatisfactory survival outcomes. Despite FDA approval in the United States, sunitinib has not been approved by the European Medicines Agency (EMA) for adjuvant use and has limited use in clinical practice, given its low benefit-risk ratio.
There have been many studies investigating potential adjuvant treatments in kidney cancer since the 1980s
The standard treatment for patients diagnosed with early-stage and/or locally advanced kidney cancer is partial or complete nephrectomy; however, cancer recurs after surgery in approximately half of patients. With this approval, for the first time, we have an effective adjuvant immunotherapy option for patients with renal cell carcinoma whose tumors have been surgically removed and who are at high risk of recurrence.
FDA Approval Based on the KEYNOTE-564 Study
A New Era Has Begun in Kidney Cancer Treatment
The effectiveness of pembrolizumab was evaluated in a multicenter, randomized (1:1), double-blind, placebo-controlled study including 994 patients with kidney cancer at intermediate-high or high risk of recurrence, or M1 disease with no evidence of disease, called KEYNOTE-564. Patients were randomized to receive intravenous pembrolizumab or placebo for up to 1 year, every 3 weeks at 200 mg, until disease recurrence or unacceptable toxicity.
The primary efficacy outcome measure was investigator-assessed disease-free survival, defined as the time to recurrence, metastasis or death. An additional outcome measure was overall survival.
Results
- With 109 (22%) events in the pembrolizumab arm and 151 (30%) events in those receiving placebo, a prespecified interim analysis showed a statistically significant improvement in disease-free survival (HR 0.68; 95% CI: 0.53, 0.87; p=0.0010). In other words, immunotherapy use increased the probability of disease-free survival by 32%.
- The median disease-free survival time was not reached in either arm.
- At the time of the disease-free survival analysis, overall survival data were immature.
The most common adverse reactions (≥20%) in patients in this trial were musculoskeletal pain, fatigue, rash, diarrhea, itching and hypothyroidism.
The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks, until disease recurrence, unacceptable toxicity or up to 12 months.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.